Expert Point of View: Biomarker Analysis of the TORCH Study: First-line Erlotinib Only in Patients with EGFR-positive Non–Small Cell Lung Cancer

Get Permission


Tetsuya Mitsudomi, MD, PhD, of Aichi Cancer Center Hospital in Nagoya, Japan, discussed the study presented by Tsao and colleagues1 and said that many previous trials have already shown that EGFR mutation is the most reliable predictive marker for treatment with EGFR tyrosine kinase inhibitors. The current analysis confirmed the importance of EGFR mutation testing when considering the use of erlotinib (Tarceva), especially in consideration of the shorter progression-free survival obtained with erlotinib when the mutation was absent. Consequently, although it was thought that erlotinib is active even in lung cancer patients without EGFR mutation if compared with gefitinib (Iressa), this study suggests that erlotinib should be avoided when treating patients without EGFR mutation, at least in the first-line setting. ■

Disclosure: Dr. Mitsudomi reported no potential conflicts of interest.


1. Tsao MS, Gallo C, Saieg M, et al: Biomarkers of TORCH trial of first-line erlotinib followed by second-line chemotherapy in advanced non-small cell lung cancer patients. European Lung Cancer Conference. Abstract 163O. Presented April 19, 2012.

Related Articles

Biomarker Analysis of the TORCH Study

Patients with advanced non–small cell lung cancer (NSCLC) should receive treatment with erlotinib (Tarceva) before receiving standard chemotherapy only if their tumor is known to harbor EGFR mutations, researchers reported at the 3rd European Lung Cancer Conference in Geneva, Switzerland.1





By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.